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Non-Technical Summary 
At present, evaluation of health programs is based principally on life expectancy due to the easier availability 
of mortality than morbidity data. Whereas mortality data are routinely collected by national registers, 
morbidity statistics are generally obtained through ad hoc surveys. Since morbidity and mortality are 
complementary aspects of a population’s health, a good measure of morbidity life expectancy (or life 
expectancy with diseases which are not necessarily limiting) should comprise both. By using the Sullivan 
method (1971), which estimates the number of years with morbidity through the product of the total 
number of person-years (from life tables) and morbidity prevalence rates, an index resulting from both 
morbidity and mortality can be derived.  
 
Any morbidity life expectancy is influenced by a range of diseases whose effect is unknown unless 
decomposition techniques are applied to determine their individual contributions. Identifying the main 
conditions which trigger the most significant numbers of years spent with morbidity would help to assess 
and target areas where the most intervention is needed. It is, therefore, worth investigating.  
 
The project aimed to apply a decomposition method to investigate the effect of the disease distribution on 
changes in morbidity life expectancies over time and on differences between the sexes.  
 
England was selected for the study since the Health Survey for England (“HSE”) includes detailed 
information on morbidity. The study was carried out on the period 1991-2005. Mortality and population 
counts were provided by the Office for National Statistics (“ONS”) whilst disease counts were drawn from 
the HSE.  
 
The morbidity life expectancies computed in the study comprised the standard measure of disability life 
expectancy (i.e. time spent living with a limiting long term illness) and a wider measure of morbidity life 
expectancy that also takes into account diseases which do not limit daily activities. Whilst data for the latter 
were available for the whole period, data for the former were only available from 1997 since it was only 
from that year that individuals were asked whether any long term illness they had was limiting. 
  
Reported diseases and disabilities were aggregated into categories. These reflected a combination of 
trauma, chronic and long term conditions, as well as infectious diseases and acute episodes. The categories 
were infections, neoplasm, cardiovascular diseases, respiratory or other chronic diseases (i.e. digestive, 
musculoskeletal, and mental diseases), and other acute diseases (i.e. endocrine, blood, genitourinary, skin, 
eye and ear diseases).  
 
In line with the official figures released by ONS, morbidity life expectancies were computed using 3-year 
data periods (i.e. 1991-1993, 1994-1996,….., 2003-2005). Therefore, the first central year in the analysis 
was 1992 and the last was 2004. Based on the survey data availability, disease and disability life 
expectancies were computed for 1991-2005 and 1997-2005, respectively.  
 
The decomposition method provided by Nussleder and Looman (2004) was applied to disentangle changes 
to the morbidity life expectancies occurring over time and differences between the sexes.  
 
Until now, the method had only been applied to obtain the effects attributable to each main disease 
separately. The focus on single diseases, as opposed to co-morbidity, can hide, however, significant 
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information in an ageing population such as that in the UK; at older ages people might suffer from multiple 
disease conditions which are not accounted for by decomposition performed purely on single disease 
categories. Therefore, for this research, the reported diseases drawn from the HSE were categorised into 
two exclusive groups: “single diseases” and “co-morbidity diseases”.  
 
Table 1 sets out a summary of some important results between 1998 and 2004. 
 
Table 1: Changes in various measures of life expectancy at age 16 between 1998 and 2004 
 
Life expectancies  
Males Females 
1998 2004 Difference 1998 2004 Difference 
       
Total life expectancy 59.7 61.5 1.8 64.5 65.7 1.2 
Years spent without 
diseases 
29.4 29.6 0.2 28.3 28.5 0.2 
Years spent without 
disabilities 
44.4 46.1 1.7 46.1 47.0 0.9 
       
Years spent with disease 30.3 31.9 1.6 36.2 37.2 1.0 
Years spent with 
disabilities 
15.3 15.4 0.1 18.4 18.7 0.3 
       
 
Table 1 suggests the following: 
 
For males: 
 
- of the 1.8 years of increased life expectancy, 0.1 years were disability free and 1.7 years were with 
disability   
- of the 1.8 years of increased life expectancy, 0.2 years were spent without disease and 1.6 years with 
disease 
- of the extra 1.6 years spent with disease, 0.2 years were due to a change in morbidity. This change 
resulted from a 1.6 years increase from multiple diseases and 1.4 years decline from single diseases. 
 
For females: 
 
- of the 1.2 years of increased life expectancy, 0.9 years were disability free and 0.3 years were with 
disability  
- of the 1.2 years of increased life expectancy, 0.2 years were spent without disease and 1.0 years with 
disease 
- the extra 1.0 years spent with disease was due entirely to increased life expectancy. The morbidity 
component as a whole did not contribute because there was a 1.5 years increase from co-morbidity and 
a 1.5 years decline from single diseases.  
 
 
 
 4
The results imply that, in recent years: 
 
a. life expectancy has been increasing for both sexes but the increase has been greater for males 
b. life expectancy with disease has increased more for males than females 
c. most of the additional years are being spent with diseases which are not limiting  
d. in the disease state, more years are being spent with co-morbidity as opposed to a single disease 
 
The research also found that the co-morbidity category “cardiovascular, respiratory or other chronic 
diseases, and other acute diseases” was a significant cause for increasing both disabled and disease life 
expectancies. 
 
The above trends have significant implications for health policy in the UK to the extent that they imply 
additional health costs and greater care needs coupled with reductions in work-related activity due to ill 
health. A further stage in this research would, therefore, be to seek to quantify these effects and investigate 
possible policies that might limit or stem their future progress. 
 
Significantly, in future, ONS intends to decompose disability life expectancy and publish the relevant health 
statistics as a result of this project. 
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Full Research Report 
 
 
Background 
 
There is an emerging debate about how increasing longevity influences health and whether the additional 
years of life are spent in good health, or with disability or disease. A population that spends more years in 
disease or disability will have the effect of increasing the demands made upon health and social care 
services. Since most disability and disease occurs in the last years of life most of these extra demands will 
come from the older population, which is expected to increase from around 11m to 16m over the next 
decade. However, despite increasing life expectancy, there are competing theories that seem to point in 
different directions as to whether a greater or lesser proportion of life is being spent in ill-health (Karlsson et 
al 2006). 
 
Part of the problem is definitional i.e. what is meant by ‘disability’, and this can frustrate comparative studies 
and often lead to divergent conclusions. A confounding problem is that is possible to suffer from a long term 
disease such as hypertension or diabetes without necessarily being ‘disabled’ to the extent that it restricts 
activities of daily living and thus disrupts normal life. A person with a long term disease will nevertheless 
make demands on health services, but not necessarily on social care. A person suffering from a disability, 
perhaps caused by a long term limiting illness, could on the other hand be expected to make demands upon 
both health and social care services. It therefore seems important to be able to disaggregate these effects, 
and track them through time to see how they change, either for better or worse. As a result of better 
measurement, society should be able to improve its knowledge and understanding not only about trends but 
also the long term effectiveness of different policies and interventions aimed, for example, at prolonging life 
and curing disease. 
 
The purpose of this paper is to explore available data in order to unpick some of these issues and make 
appropriate estimates of their effects using data from the UK. At present, evaluation of health programs is 
based principally on life expectancy due to the easier availability of mortality than morbidity data. Whereas 
vital statistics are routinely collected by national registers, morbidity statistics are generally obtained through 
ad hoc surveys. In England and Wales the largest surveys collecting morbidity information are the General 
Household Survey (GHS) and the Health Survey for England (HSE). 
 
Since morbidity and mortality are complementary aspects of a population’s health, a good measure of health 
should comprise both. By using the Sullivan method (1971), which estimates the number of years with 
morbidity through the product of the total number of person-years (from life tables) and morbidity 
prevalence rates, an index resulting from both morbidity and mortality can be derived. On these grounds, 
the Sullivan method is a valuable tool for the verification and monitoring of a population’s health and in the 
UK is applied to compute activity-limiting long-term illness life expectancy (generally called “disability life 
expectancy” - see Kelly et al 2000; Breakwell & Bajekal 2006).  
 
Disability life expectancy in the UK is obtained through responses to survey questions. There is substantial 
controversy in the literature over the use of self-reported disability on the grounds that a respondent may 
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inflate the severity of his/her health problems in order to justify labour force non-participation and disability 
benefits (Benitez-Silva et al 2004). Also, disability rates do not include morbidity conditions which are not 
limiting but nevertheless require regular access to health services. As people might spend more years with 
“not limiting” diseases, morbidity measures which provide a wider coverage of a population’s health are 
desirable depending on their purpose.  
Any morbidity life expectancy (or life expectancy with long-term illness but not necessarily limiting) is 
influenced by a range of diseases whose effect is unknown unless decomposition or cause-elimination 
techniques are applied to determine their individual contributions in comparable units (in this case years). 
Recent research has, for instance, found that respiratory diseases are responsible for a significant proportion 
of serious morbidity in the UK and that, as a result, more resources may be needed to tackle this burden 
(Chung et al 2002). Identifying the main conditions which trigger the greatest numbers of years spent with 
morbidity would help to assess and target areas where the most intervention is needed and is, therefore, 
worth investigating. A decomposition method which enables the identification of the main causes influencing 
disability life expectancy is available. Up to now, the method has only been applied to obtain the effects 
attributable to each main disease separately. This was the approach adopted by Nussleder and Looman 
(2004) when they applied it to Dutch data.  
 
The focus on single diseases, as opposed to co-morbidity, can hide, however, significant information in an 
ageing population such as that in the UK; at older ages people might suffer, in fact, from multiple disease 
conditions (Cornoni-Huntley et al 1991; Guralnik 1996; Rijken et al 2005) which are not accounted for by 
decomposition performed on single disease categories.  
 
In response to these key issues, the project aimed to compute, along with the standard measure of disability 
life expectancy, a measure that could provide a more objective and wider coverage of a population’s health 
that takes into account the fact that diseases may not be ‘limiting”. Furthermore, we wished to investigate 
changes in disability life expectancy which are due to co-morbidity conditions as well as single diseases.  
 
 
Objectives 
 
The initial aims of the project were to: 
 
a. Compute disability-free life expectancy in England using the HSE from 1991 to 2001 
b. Apply the decomposition method of Nussleder and Looman (2004) to explain changes in this 
measure over time for each sex  
c. Identify the single diseases which account for the changes. 
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The first aim was altered in four ways: 
 
1. The availability of surveys and mortality rates up to 2005, rather than just 2001, led to the period of 
analysis being extended. This enabled a more complete investigation of the population’s health in 
England to be carried out 
2. “Disability life expectancy” was preferred to “disability-free life expectancy” as a measure since the 
former can be computed using disability prevalence rates and, therefore, better reflects changes in 
morbidity conditions 
3. Along with “disability life expectancy”, an additional measure of morbidity life expectancy was 
computed: “disease life expectancy”. This was expected time spent with a disease which was not 
necessarily “limiting” in nature 
4. The HSE did not include until 1997 a question needed for the computation of disability life 
expectancy; hence this measure was computed from 1997 onwards rather than 1991 as planned.  
 
The second aim was extended by investigating differences between the sexes as well as changes within 
each sex over time. 
 
The third aim was expanded by identifying the effect which co-occurring diseases, as well as single diseases, 
had on each morbidity life expectancy measure. 
 
 
Method 
Data 
 
In order for the Sullivan method (1971) to be applied, mortality rates and prevalence morbidity rates are 
required. Hence, the data needed to comprise death, population and morbidity counts by sex and age. 
Mortality and population counts were provided by the Office for National Statistics (ONS) whilst morbidity 
counts were drawn from the HSE. 
  
Sample sizes by sex for each survey year are shown in Table 1. The survey includes questions on the 
occurrence of long-term and limiting long-term illness, and on the occurrence of conditions that require 
medicine to be taken regularly. 
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Table 1. Health Survey for England between 1991 and 2005. Sample size for aged 16 and over.  
 
HSE surveys Males Females 
 1991 1,492 1,750 
 1992 1,868 2,150 
 1993 8,416 9,271 
 1994 7,178 8,631 
 1995 7,335 8,720 
 1996 7,486 8,957 
 1997 3,898 4,684 
 1998 7,193 8,715 
 1999 3,558 4,240 
 2000 4,266 6,215 
 2001 6,966 8,681 
 2002 4,543 5,788 
 2003 6,602 8,234 
 2004 2,879 3,825 
 2005 4,629 5,674 
Source: HSE 
 
Respondents with a long-term illness could list up to six illnesses, which were categorised according to the 
classification adopted for deaths.  
 
The prescribed medicine classification was used to categorise the respondents within disease groupings and 
the information was later used to investigate the morbidity conditions having the greatest influence on 
morbidity life expectancy. The prescribed medicine classification was available for every year of the survey 
except 1996.  
 
The counts from the questions on long-term illness and medicine were used to obtain the wider measure of 
morbidity, “disease life expectancy”. The question on limiting illness, used for the computation of disability 
life expectancy, was included for the first time in 1997.  
 
The long-term illnesses and the diseases treated with the prescribed medicine were aggregated in five broad 
categories. These reflect a combination of trauma, chronic and long term conditions, as well as infectious 
diseases and acute episodes and were informed by the terminology used in the HSE. The categories are 
infections, neoplasm, cardiovascular diseases, respiratory or other chronic diseases (i.e. digestive, 
musculoskeletal, and mental diseases), and other acute diseases (i.e. endocrine, blood, genitourinary, skin, 
eye and ear diseases). These categories represented the single diseases used in the decomposition analysis.  
 
Co-morbidity was obtained by combining the five disease categories and, for the decomposition analysis, the 
co-morbidities having the greatest effect on disease life expectancy were kept: 
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- “cardiovascular” and “respiratory or other chronic diseases” 
- “cardiovascular” and “other acute diseases” 
- “respiratory or other chronic diseases” and “other acute diseases”  
- “cardiovascular” and “respiratory or other chronic diseases” and “other acute diseases”  
- the remaining  co-morbidity conditions.  
 
Each respondent to the HSE survey was included only in one category (either single or multiple diseases).  
 
Methodology  
 
The Sullivan method requires morbidity prevalence rates and person-years from life tables, whose product 
provides the person-years with morbidity. In line with the official figures released by the Government 
Actuary’s Department and the ONS, life tables were computed using 3-year data periods (i.e. 1991-1993, 
1994-1996,….., 2003-2005). Therefore, the first central year in the analysis was 1992 and the last was 2004. 
Disease and disability rates were similarly obtained using 3-year survey periods. Based on the survey data 
availability, disease and disability life expectancies covered the periods 1991-2005 and 1997-2005 
respectively.  
 
The decomposition method (Nussleder & Looman 2004) was applied to disentangle changes to the morbidity 
life expectancies occurring over time for each sex and differences in morbidity life expectancies between the 
sexes. The method separates the mortality and morbidity contributions to morbidity life expectancy. For 
example, a change over time is decomposed according to the following formula:  
 
⎟⎠
⎞⎜⎝
⎛ ++⎟⎠
⎞⎜⎝
⎛ += ++
22
nttntt
morb
LLLL δπππδδ      (1) 
 
Where Lmorb represents the person-years with morbidity, L represents the total number of person-years, π is 
the prevalence morbidity rate,  and δ is the symbol for a change over time (of for a difference between the 
sexes depending on the decomposition purpose). t refers to the first time point of the decomposition and 
t+n to the second time point of the analysis; in a decomposition between the sexes t and t+n refers to the 
male and female populations. It is important to note that, in all of the analysis which follows, the first 
component of the morbidity life expectancy shown in equation (1) is the “mortality component” and the 
second is the “morbidity component”. 
 
The decomposition was applied to explain: 
 
- the changes in both disabled life expectancy and disease life expectancy between 1992 and 2004, 1992   
and 1998, and 1998 and 2004  
- the differences in these measures between the sexes in 1992, 1998 and 2004.  
 
All analyses were performed using STATA (a statistical computer package). 
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Results 
Life expectancy with and without disease and disability 
 
Table 2 shows for each sex the total life expectancy, the disease and disability life expectancies at age 16 
and the variation which occurred between 1992 and 2004.  
 
In 12 years the total life expectancy increased by 3.1 years for males and 2.0 years for females. For both 
sexes the change was greater in the most recent period (1998-2004) when males gained 1.8 years and 
females 1.2 years. 
 
Life expectancy with diseases increased more rapidly than total life expectancy and this pattern was more 
evident for males than females (5.2 vs 2.6 years). The greatest change occurred in the earlier period (1992-
1998) when males gained 3.6 years and females 1.7 years. 
 
These findings suggest that total and disease life expectancies did not increase at the same rate and the 
majority of the increase occurred in different time periods from one another (i.e. 1992-1998 for disease life 
expectancy and 1998-2004 for total life expectancy).  
 
Between 1998 and 2004 the number of years with disability increased by 0.1 years for males and 0.3 years 
for females compared to a change of 1.6 and 0.9 years in disease life expectancy. Hence, if the additional 
measure of disease life expectancy had not been computed, morbidity in England would have been 
underestimated by 1.5 years for males and 0.6 years for females.  
 
It appears that the proportion of life spent with disease is considerable and much higher than for disability 
life expectancy. For example, amongst females, the disease life expectancy was approximately 56 per cent 
of total life expectancy during the period 1992 to 2004, whereas disability life expectancy was about 28 per 
cent of the total life expectancy in 1998 and in 2004. Males tended to spend a smaller proportion of their 
lives with disability or disease than females (approximately 48 per cent and 25 per cent, respectively). 
 
It should be noted that, because the HSE is carried out on households, people residing in institutional care 
homes are not included. This might cause life expectancies with disease or disability to be underestimated. 
However, based on past research, which found that allowing for the institutional population does not alter 
the disability-free life expectancy at birth significantly (Bebbington and Darton 1996), any underestimation is 
likely to be small.  
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Table 2. Total, disease and disability life expectancies at age 16 by sex and year.  
 
Years Males Females 
Total LE Disease LE Disability LE Total LE Disease LE Disability LE 
1992 58.4 26.7 
[26.2 - 27.2] 
- 63.7 34.5 
[34.0 – 35.0] 
- 
1993 58.7 27.7 
[27.3 - 28.1] 
- 63.9 35.2 
[34.8 – 35.6] 
- 
1994 58.8 28.4 
[28.1 - 28.8] 
- 63.9 35.5 
[35.2 – 35.9] 
- 
1995 59.1 - - 64.1 - - 
1996 59.2 - - 64.2 - - 
1997 59.5 - - 64.4 - - 
1998 59.7 30.3 
[29.9 – 30.8] 
15.3 
[14.9 – 15.7] 
64.5 36.2 
[35.8 – 36.7] 
18.4 
[18.0 – 18.8] 
1999 60.0 30.4 
[29.9 - 30.8] 
15.0 
[14.6 – 15.4] 
64.7 36.4 
[35.9 – 36.8] 
16.9 
[16.5 – 17.3] 
2000 60.3 30.6 
[30.2 - 31.1] 
14.9 
[14.5 – 15.3] 
64.9 36.9 
[36.5 – 37.3] 
17.1 
[16.7 – 17.5] 
2001 60.6 32.0 
[31.6 - 32.4] 
15.1 
[14.7 – 15.5] 
65.2 39.0 
[38.6 – 39.4] 
17.4 
[17.0 – 17.8] 
2002 60.9 32.3 
[31.9 - 32.7] 
15.5 
[15.1 – 15.9] 
65.3 38.9 
[38.5 – 39.3] 
18.8 
[18.4 – 19.2] 
2003 61.2 31.9 
[31.4 - 32.4] 
15.6 
[15.2 – 16.1] 
65.5 37.6 
[37.1 – 38.0] 
18.9 
[18.5 – 19.3] 
2004 61.5 31.9 
[31.5 - 32.4] 
15.4 
[15.0 – 15.8] 
65.7 37.2 
[36.7 – 37.6] 
18.7 
[18.3 – 19.2] 
       
Change 1992-2004 3.11 5.26  2.00 2.65  
Change 1992-1998 1.30 3.62  0.80 1.72  
Change 1998-2004 1.81 1.64 0.07 1.20 0.93 0.32 
Source: own analysis on ONS and HSE data 
 
Decomposition of changes to disease life expectancies  
 
Changes in the decomposition of disease life expectancy over time are shown in Table 3. Each change was 
separated into the mortality and morbidity effects, and the latter was further decomposed into single and co-
occurring disease components. A negative sign for the morbidity component is actually a positive feature: it 
suggests individuals are spending less time with disease than at the earlier time point.  
 
For males, the disease life expectancy increased by 5.3 years between 1992 and 2004; 2.9 years of this 
change were due to increased morbidity and 2.4 to increased life expectancy. Most of the morbidity increase 
occurred in the earlier sub-period (i.e. 1992-1998). Similar comments can be made about females. 
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Table 3. Changes in disease life expectancy over time. Mortality and morbidity effects. 
Changes Males Females 
1992 vs 2004 1992 vs 1998 1998 vs 2004 1992 vs 2004 1992 vs 1998 1998 vs 2004 
       
Total change  5.26 3.62  1.64  2.65  1.72  0.93 
       
Decomposition       
Mortality change  2.40 0.98  1.42  1.59  0.62  0.97 
Morbidity change  2.86 2.64  0.22  1.06  1.10  -0.04 
       
Decomposition of 
morbidity 
      
Single diseases -0.39 1.04 -1.43 -2.57 -1.04 -1.53 
Co-morbidity  3.25 1.60  1.65  3.63  2.14  1.49 
       
Source: own analysis on ONS and HSE data 
 
The results for single and co-occurring diseases are presented in Figure 1.  
 
For males, between 1992 and 2004 the years spent with single diseases decreased with the exception of 
those spent with cancer which rose by 0.2 years and those spent with “respiratory or other chronic diseases” 
which rose by 0.7 years. Amongst co-morbidities, the biggest disease life expectancy increase occurred for 
the category comprising “cardiovascular diseases”, “respiratory or other chronic diseases”, and “other acute 
diseases” (0.9 years).  
 
For females, the biggest change in disease life expectancy occurred for the co-morbidity category comprising 
“cardiovascular”, “respiratory or other chronic diseases”, and “other acute diseases” which increased by 1.4 
years.  
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Figure 1. Decomposition of the morbidity effect accounting for changes in disease life expectancy.  
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Source: own analysis on ONS and HSE data 
Note: In the co-morbidity categories the abbreviation “Chronic” refers to “Respiratory or other chronic” diseases 
 
 
Decomposition was also used to explain differences between the sexes. A positive sign for the morbidity 
category means that the morbidity rates are larger for females than males whilst a positive sign for the 
mortality category indicates that females survive longer than males.  
 
The decomposition between females and males was performed for 1992, 1998 and 2004. Table 4 shows that 
in 1992 females spent 7.8 years longer with disease than males; the gap dropped to 5.2 years in 2004.  
 
In terms of reported diseases, the greater number of years spent with diseases by females was caused by 
higher prevalence rates of “other acute diseases”, which accounted for 3.3 years in 1992 and 1.8 years in 
2004 (Figure 2).  
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Table 4. Differences between the sexes (females vs males) in disease life expectancy.  
Mortality and morbidity effects. 
Differences 1992 1998 2004 
    
Total difference 7.84 5.93 5.23 
    
Decomposition    
Mortality difference 3.77 3.63 3.30 
Morbidity difference 4.07 2.30 1.93 
    
Decomposition of morbidity    
Single diseases 2.90 0.82 0.85 
Co-morbidity 1.17 1.48 1.08 
    
Source: own analysis on ONS and HSE data 
 
Figure 2. Decomposition of the morbidity effect accounting for differences in disease life expectancy 
between the sexes (females vs males)  
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Source: own analysis on ONS and HSE data 
 
 
Decomposition of changes to disability life expectancy  
 
Between 1998 and 2004, disability life expectancy gained about 0.1 years for males and 0.3 years for 
females (Table 5); these changes result from the counterbalancing values of mortality and disability.  
 
For males, the mortality component increased by 0.8 years whilst the disability component decreased by 0.7 
years causing a total change of 0.1 years in disability life expectancy.  
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For females, the mortality component increased by 0.6 years and the disability went down by 0.3 years 
leading to a change of 0.3 years.  
 
Therefore, for both sexes most of the increase in life expectancy was spent without disabilities. 
 
Analysing the decomposition of morbidity into their single and co-occurring disability components, the 
morbidity component was negative overall because the decrease from the single disability component more 
than offset the increase from the co-morbidity component. Between 1998 and 2004 the life spent with 
multiple disabilities increased by 0.5 years for males and 0.9 years for females. However, because of a larger 
decline of life spent with single diseases, there was an overall improvement in the quality of survival.  
 
Table 5. Change in disability life expectancy over time, 1998-2004. Mortality and morbidity effects. 
Changes Males Females 
   
Total change  0.07  0.32 
   
Decomposition   
Mortality change  0.83  0.62 
Morbidity change -0.76 -0.30 
   
Decomposition of morbidity   
Single diseases -1.25 -1.20 
Co-morbidity  0.49  0.90 
   
 
Decomposition into disability causes shows that the biggest change between 1998 and 2004 occurred for the 
life expectancy with “respiratory and other chronic diseases” which declined by about 0.6 years for both 
sexes (Figure 3). This is an encouraging finding. 
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Figure 3. Decomposition of the disability effect accounting for changes in disability life expectancy. 
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Source: own analysis on ONS and HSE data 
 
 
Regarding differences between the sexes, in 1998 and 2004 females spent about three more years with 
disability than males (Table 6). Most of the increase is attributable to pure survival, with the rest mainly due 
to the effect of co-morbidity. Life expectancy with single and co-occurring disabilities were higher for 
females than males.  
 
Table 6. Differences between the sexes (females vs males) in disease life expectancy. Mortality and 
morbidity effects. 
Differences 1998 2004 
   
Total difference 3.1 3.3 
   
Decomposition   
Mortality difference 2.3 1.9 
Morbidity difference 0.8 1.4 
   
Decomposition of morbidity   
Single diseases 0.1 0.3 
Co-morbidity 0.7 1.1 
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By partitioning the single and co-morbidity categories into the reported disability categories (Figure 4), it 
transpired that females lived from 0.1 to 0.6 years longer than males with any disability apart from 
“cardiovascular diseases” and “cardiovascular and other acute diseases”, where the prevalence rates were 
higher for males.  
 
Figure 4. Decomposition of the disability effect accounting for differences in limiting long-term illness life 
expectancy between the sexes (females vs males). 
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Discussion 
 
We have discussed two types of life expectancy with disease: “disability life expectancy” which is the years 
spent with long term conditions that affect daily activities and “disease life expectancy” which is the years 
spent with diseases that may or may not be limiting daily activities. These measures were used to analyse 
changes over time, and to attribute changes to specific categories of disease. The results appear to suggest 
important trends which have implications both for the health of the population and for health policy. 
 
The findings point to extension of life together with expansion of time spent with disease. However, because 
morbidity life expectancy time increasing or decreasing is a result of both mortality and morbidity prevalence 
rates, any conclusions about morbidity trends should follow from decomposition into the two components.  
 
Through the application of the Nussleder and Looman method (2004) on changes in disease life expectancy, 
the study found that an increasing amount of time was spent with disease between 1992 and 1998; whereas 
it was fairly stable between 1998 and 2004 - the majority of the change in disease life expectancy reflected 
life extension.  
 
Increases, reductions or stability in morbidity life expectancy stem from the pattern of the contributing 
diseases. In this study, these are given by the broad categories “single diseases” and “co-occurring diseases” 
and by the specific diseases contained within those two categories. The results suggest that morbidity 
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expansion between 1992 and 1998 was mainly driven by an increase in the co-morbidity component whilst 
morbidity stability between 1998 and 2004 was a result of the trends in single and co-occurring diseases 
offsetting one another.  
 
The increase in the co-morbidity contribution to disabled life expectancy can be explained by the fact that 
the population is ageing. Older people are more likely than younger people to have several co-existing 
health problems (Cornoni-Huntley et al 1991; Guralnik 1996; Rijken et al 2005).  
 
Between 1998 and 2004, the morbidity component did not have the same effect on disease life expectancy 
as it did on disability life expectancy. Despite the increase in both measures of morbidity life expectancies, 
the morbidity component was practically stable for disease life expectancy and declined for disability life 
expectancy. The findings suggest that, as life expectancy increases, the number of years spent with 
morbidity (computed through the Sullivan method) increases; this accords with a study forecasting future 
disability levels (Jagger et al. 2006).  
 
Co-morbidity provided a larger contribution to differences between the sexes in disability life expectancy 
than disease life expectancy. This is consistent with the higher life expectancy of females and with the fact 
that disability is more prevalent at older ages.  
 
In conclusion, it is emphasised that, compared to the Nusselder and Looman study (2004), the total 
morbidity effect was split into the separate contributions from single and co-occurring diseases. Since time 
spent with co-morbidities has been increasing and time spent with single morbidities has been decreasing 
estimates unadjusted for co-morbidity would have overestimated the effect of single diseases.  
The study proposed a measure (i.e. disease life expectancy) which provides a wider coverage of morbidity 
conditions than the disability life expectancy and a more objective measure of morbidity than those based on 
self assessed health conditions.  
 
Table 7 sets out a summary of the various life expectancy measures discussed in this work between 1998 
and 2004. It suggests that: 
 
- For males, disability-free life expectancy increased by 1.7 years. This implies that of the 1.8 years in 
increased life expectancy, 0.1 years were disability free and 1.7 years were spent with disability  
- For females, disability-free life expectancy increased 0.9 years. This implies that of the 1.2 years in 
increased life expectancy, 0.9 years were disability free and 0.3 years were spent with disability.  
 
- Disease-free life expectancy for males increased by 0.2 years. Therefore, of the 1.8 years of increased 
life expectancy, 0.2 years were spent without disease and 1.6 years with disease 
- Disease-free life expectancy for females also increased by 0.2 years. Therefore, of the extra 1.2 years 
of life expectancy, 0.2 years were spent without disease and 1.0 years with disease. 
 
- For males, of the extra 1.6 years spent with disease, 0.2 years were due to a change in morbidity. This 
change resulted from 1.6 years increase from multiple diseases and 1.4 years decline from single 
diseases. 
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- For females, the extra 1.0 years spent with disease was due entirely to increased life expectancy. The 
morbidity component as a whole did not contribute because there was a 1.5 years increase from co-
morbidity and a 1.5 years decline from single diseases.  
 
 
Table 7 Changes in various measures of life expectancy between 1998 and 2004 
Life expectancies 
Males Females 
1998 2004 Difference 1998 2004 Difference 
       
Total life expectancy 59.7 61.5 1.8 64.5 65.7 1.2 
Years spent without diseases 29.4 29.6 0.2 28.3 28.5 0.2 
Years spent without disabilities 44.4 46.1 1.7 46.1 47.0 0.9 
       
Years spent with disease 30.3 31.9 1.6 36.2 37.2 1.0 
Years spent with disabilities 15.3 15.4 0.1 18.4 18.7 0.3 
       
 
These results imply that: 
 
- life expectancy is increasing for both males and females but the increase is larger for males 
- life expectancy with disease has increased more for males than for females 
- most of the additional years are being spent with diseases which are not limiting  
- in the disease state, more years are being spent with co-morbidity as opposed to a single disease. 
 
These trends, if accurately reflected in the data and methodology, thus have significant implications for 
health policy in the UK to the extent that they imply additional health costs and greater care needs, coupled 
with reductions in work related activity due to ill health. A further stage in this research therefore would be 
to seek to quantify these effects and investigate possible policies that might limit or stem their future 
progress. 
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